This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Menu
Close
Click here for HYMPAVZI®▼ (marstacimab) Prescribing Information.
Example
HYMPAVZI is indicated for routine prophylaxis of bleeding episodes in patients 12 years of age and older, weighing at least 35kg, with:
- severe haemophilia A (congenital factor VIII deficiency, FVIII <1%) without factor VIII inhibitors, or
- severe haemophilia B (congenital factor IX deficiency, FIX <1%) without factor IX inhibitors1,2
On May 21st 2025, NICE published Final Draft Guidance (FDG) recommending HYMPAVZI, within its marketing authorisation, as an option for preventing bleeding episodes caused by severe (factor IX [9] activity less than 1%) haemophilia B (congenital factor 9 deficiency) in people 12 years and over who:
The HYMPAVZI Formulary Guide details key information about the product to support with fomulary applications.
On 24th June 2025, NICE published Final Guidance (FG) TA1073 recommending HYMPAVZI, within its marketing authorisation, as an option for preventing bleeding episodes caused by severe (factor IX [9] activity less than 1%) haemophilia B (congenital factor 9 deficiency) in people 12 years and over who:
- weigh at least 35kg and
- do not have factor 9 inhibitors (anti-factor antibodies).3
As part of the Innovative Medicines Fund, interim funding has been agreed for HYMPAVZI. Interim funding will end 90 days after positive final guidance is published, 24th September 2025, at which point funding will switch to routine commissioning budgets.3
Click here to read the NICE FG for HYMPAVZI in full.
The HYMPAVZI Formulary Guide details key information about the product to support with formulary applications.
HYMPAVZI is a human monoclonal antibody directed against tissue factor pathway inhibitor (TFPI).1 See how HYMPAVZI acts within in the coagulation cascade:
HYMPAVZI is the first and only once-weekly subcutaneous prophylactic treatment for severe haemophilia without inhibitors that comes in a pre-filled fixed dose pen.1 Watch how HYMPAVZI is adminstered:
HYMPAVZI is intended for use under the guidance of a healthcare professional. After proper training in subcutaneous injection technique, a patient may self-inject, or the patient's caregiver may administer HYMPAVZI, if a healthcare professional determines that it is appropriate.1
Treatment should be initiated under the supervision of a healthcare profesional experienced in the treatment of haemophilia. Treatment should be initiated in a non-bleeding state. For more information, consult the summary of product characteristics.1
Kiran
Healthcare Partnership Manager
Key HYMPAVZI point of contact for South of England, East of England, London & Wales.
Andrew
Healthcare Partnership Manager
Key HYMPAVZI point of contact for Midlands, North of England, Scotland & Northern Ireland.
Victoria
Rare Disease Network Lead
Key point of contact for national access, educational opportunities and professional relations.
Be the first to know about product updates, events, and more.
References:
1. HYMPAVZI (marstacimab) UK Summary of Product Characteristics.
2. HYMPAVZI (marstacimab) UK Patient Information Leaflet.
3. NICE TA1073. Marstacimab for treating severe haemophilia A or B in people 12 years and over without anti-factor antibodies. Available from: https://www.nice.org.uk/guidance/ta1073/resources/marstacimab-for-treating-severe-haemophilia-a-or-b-in-people-12-years-and-over-without-antifactor-antibodies-pdf-2973528634879429 (Accessed June 2025)
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2025 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024.